Form 4 for ANTX AN2 Therapeutics, Inc.

Accepted 2023-08-25 00:00:00 ET · period of report 2023-08-23 · accession 0000950170-23-044594 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2023-08-25	2023-08-23	ANTX	Adjuvant Capital GP, L.P.	10%	S - Sale	$16.00	-336	2.18M	-0.0%	-$5,376
I	2023-08-25	2023-08-23	ANTX	Adjuvant Capital GP, L.P.	10%	S - Sale	$16.00	-64	413.1K	-0.0%	-$1,024

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-08-23	S	D	336	$16.00	2,183,888	D By Adjuvant Global Health Technology Fund DE, L.P.	—	—	(F1) Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. (F2) Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
2	Common	Common Stock	2023-08-23	S	D	64	$16.00	413,092	I	—	—